Cellectis Ads Each Repr 1 Ord Spon2025财年第二财季实现净利润-24.04百万美元，同比增加4.87%

市场透视2025-08-11

8月11日，Cellectis Ads Each Repr 1 Ord Spon（CLLS.US）公布财报，公告显示公司2025财年第二财季净利润为-24.04百万美元，同比增加4.87%；其中营业收入为16.94百万美元，同比增加110.17%，每股基本收益为-0.24美元。从资产负债表来看，Cellectis Ads Each Repr 1 Ord Spon（CLLS.US）总负债2.57...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2558684831?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-11 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2558684831","market":"us","top_or_hot":-1,"title":"Cellectis Ads Each Repr 1 Ord Spon2025财年第二财季实现净利润-24.04百万美元，同比增加4.87%","media":"市场透视","content":"<div>\n<p>8月11日，Cellectis Ads Each Repr 1 Ord Spon（CLLS.US）公布财报，公告显示公司2025财年第二财季净利润为-24.04百万美元，同比增加4.87%；其中营业收入为16.94百万美元，同比增加110.17%，每股基本收益为-0.24美元。从资产负债表来看，Cellectis Ads Each Repr 1 Ord Spon（CLLS.US）总负债2.57...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000048a48055e9&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cellectis Ads Each Repr 1 Ord Spon2025财年第二财季实现净利润-24.04百万美元，同比增加4.87%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCellectis Ads Each Repr 1 Ord Spon2025财年第二财季实现净利润-24.04百万美元，同比增加4.87%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-11 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000048a48055e9&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月11日，Cellectis Ads Each Repr 1 Ord Spon（CLLS.US）公布财报，公告显示公司2025财年第二财季净利润为-24.04百万美元，同比增加4.87%；其中营业收入为16.94百万美元，同比增加110.17%，每股基本收益为-0.24美元。从资产负债表来看，Cellectis Ads Each Repr 1 Ord Spon（CLLS.US）总负债2.57...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000048a48055e9&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CLLS","symbol_name":"Cellectis S.A.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000048a48055e9&s=b","article_id":"2558684831","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000048a48055e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2558684831","pubTimestamp":1754841632,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"8月11日，Cellectis Ads Each Repr 1 Ord Spon公布财报，公告显示公司2025财年第二财季净利润为-24.04百万美元，同比增加4.87%；其中营业收入为16.94百万美元，同比增加110.17%，每股基本收益为-0.24美元。从资产负债表来看，Cellectis Ads Each Repr 1 Ord Spon总负债2.57亿美元，其中短期债务25.71百万美元，资产负债比为1.38，流动比率为1.39。机构评级：截至2025年8月11日，当前有7家机构对Cellectis Ads Each Repr 1 Ord Spon目标价做出预测，其中目标均价为5.50美元，其中最低目标价为3.00美元，最高目标价为10.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"CLLS":"Cellectis S.A."},"translate_title":"Cellectis Ads Each Repr 1 Ord Spon2025 Net profit in the second quarter of fiscal year was-24.04 million US dollars, a year-on-year increase of 4.87%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLLS":0.9},"content_text":"8月11日，Cellectis Ads Each Repr 1 Ord Spon（CLLS.US）公布财报，公告显示公司2025财年第二财季净利润为-24.04百万美元，同比增加4.87%；其中营业收入为16.94百万美元，同比增加110.17%，每股基本收益为-0.24美元。从资产负债表来看，Cellectis Ads Each Repr 1 Ord Spon（CLLS.US）总负债2.57亿美元，其中短期债务25.71百万美元，资产负债比为1.38，流动比率为1.39。机构评级：截至2025年8月11日，当前有7家机构对Cellectis Ads Each Repr 1 Ord Spon目标价做出预测，其中目标均价为5.50美元，其中最低目标价为3.00美元，最高目标价为10.00美元。公司简介：Cellectis SA是一家临床阶段生物技术公司，其采用核心专有技术开发基于基因编辑的产品，产品组合包括同种异体嵌合抗原受体T细胞(UCART)、免疫肿瘤学领域的产品候选物以及用于其他治疗适应症的基因编辑的造血干细胞和祖细胞(HSPC)产品候选物。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2558684831","isCrawlerRequest":true}